ATH 0.00% 0.3¢ alterity therapeutics limited

Ann: First Patient Enrolled in Australia in global Phase 2 Trial, page-2

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 923 Posts.
    lightbulb Created with Sketch. 164
    Does anyone know if when they say that they expect to enrol 60 patients, if that’s a global total or just for the Australian study? Given that the study will go for 12 months, it’s most likely the end of next year, at the earliest, before the results of the trials are announced.

    Given the cash they have available, it is also most unlikely that they will have sufficient funds to complete the trial. It’s almost a certain that there will be a capital raising during the next 12 months and at a time when the share price will be at an all time low. In their last phase 2 trial with PBT2, there was a strong run up in share price to over $1.00. Not sure we will see the same trend this time around.
 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
(20min delay)
Last
0.3¢
Change
0.000(0.00%)
Mkt cap ! $15.96M
Open High Low Value Volume
0.4¢ 0.4¢ 0.3¢ $3.516K 1.112M

Buyers (Bids)

No. Vol. Price($)
75 108230584 0.2¢
 

Sellers (Offers)

Price($) Vol. No.
0.4¢ 151421887 64
View Market Depth
Last trade - 13.21pm 06/11/2024 (20 minute delay) ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.